Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Target Price at $112.44

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average rating of “Hold” by the twenty-one analysts that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $113.1579.

A number of research analysts have recently weighed in on ZBH shares. Raymond James Financial increased their price target on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Rothschild & Co Redburn assumed coverage on Zimmer Biomet in a research note on Thursday, September 18th. They issued a “buy” rating and a $130.00 price target on the stock. UBS Group raised their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research note on Friday, August 8th. Royal Bank Of Canada set a $111.00 price objective on Zimmer Biomet in a research note on Friday. Finally, Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th.

Zimmer Biomet Stock Performance

ZBH stock opened at $95.13 on Tuesday. The business’s fifty day moving average is $101.36 and its 200-day moving average is $98.03. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The company has a market cap of $18.85 billion, a P/E ratio of 23.15, a price-to-earnings-growth ratio of 2.18 and a beta of 0.67. Zimmer Biomet has a twelve month low of $89.22 and a twelve month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts forecast that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.70% of the company’s stock.

Institutional Trading of Zimmer Biomet

Several hedge funds have recently added to or reduced their stakes in ZBH. Garde Capital Inc. acquired a new stake in Zimmer Biomet during the 1st quarter worth $29,000. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet during the 1st quarter worth about $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet during the 1st quarter worth about $30,000. Cary Street Partners Investment Advisory LLC increased its holdings in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares in the last quarter. Finally, Accent Capital Management LLC bought a new position in Zimmer Biomet during the 1st quarter worth about $35,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.